Immunocore says Kimmtrak lifts 5-year survival to 16% in metastatic uveal melanoma trial

• Immunocore reported five-year follow-up from Phase 3 trial of KIMMTRAK in previously untreated metastatic uveal melanoma, with results presented at AACR 2026.
• Study showed patients on KIMMTRAK were more likely to be alive at five years than those given investigator’s choice therapy.
• Benefit held across key high-risk patient groups, supporting KIMMTRAK’s position as first-line standard of care for eligible HLA-A*02:01-positive patients.
• Data indicated long-term survival was mainly driven by starting KIMMTRAK up front rather than later treatment switches.
• Management highlighted extended survival even when scans showed early disease worsening, backing continued use beyond initial progression in selected patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunocore Holdings plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604191800PRIMZONEFULLFEED1001176572) on April 19, 2026, and is solely responsible for the information contained therein.